Fortress Biotech, Inc. (FBIO) Free cash flow 2016–2024
Fortress Biotech, Inc. (FBIO) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$80.2MFY2024 · since FY2016: -$52.2M → -$80.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$80.2M | +37.5% |
| FY2023 | -$128.3M | +29.6% |
| FY2022 | -$182.1M | -50.4% |
| FY2021 | -$121.1M | -41.5% |
| FY2020 | -$85.6M | +12.0% |
| FY2019 | -$97.3M | +8.1% |
| FY2018 | -$105.9M | -29.3% |
| FY2017 | -$82.0M | -57.1% |
| FY2016 | -$52.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More FBIO financial trends
FBIO RevenueFBIO Net incomeFBIO Net marginFBIO Gross profitFBIO Gross marginFBIO Operating incomeFBIO Operating marginFBIO Operating cash flowFBIO Capital expendituresFBIO Return on equityFBIO Stock buybacksFBIO Dividends paidFBIO Total assetsFBIO Total liabilitiesFBIO Shareholders’ equityFBIO overview →